Zobrazeno 1 - 10
of 121
pro vyhledávání: '"35"'
Publikováno v:
Scopus-Elsevier
PURPOSE This prospective phase II study was designed to test the activity and toxicity of a regimen of fluorouracil (5-FU) and cisplatin (CDDP) in combination with radiation therapy in the treatment of epidermoid cancer of the anal canal. PATIENTS AN
Autor:
Polina Kaplan, Javier de la Serna, Malgorzata Wach, Sean Dolan, Phillip L. Campbell, Jae Hoon Lee, Martin Simkovic, Árpád Illés, Iryna Kraychok, Eric J. Avery, Wojciech Jurczak, Andrzej Pluta, Abraham Jacob, Tomas Kozak, Gerardo Musuraca, Daniel Lysák, Wei Liang, Priti Patel, Cheng Quah, Paolo Ghia
Publikováno v:
Journal of Clinical Oncology. 38:2849-2861
PURPOSE Acalabrutinib, a highly selective, potent, Bruton tyrosine kinase inhibitor, was evaluated in this global, multicenter, randomized, open-label, phase III study in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). MET
Autor:
Maximilian Hochmair, Sang-We Kim, Frank G. Haluska, Edward S. Kim, Luis Paz-Ares Rodríguez, Karen L. Reckamp, Howard West, Egbert F. Smit, William M. Reichmann, David Kerstein, D. Ross Camidge, Rudolf M. Huber, Scott N. Gettinger, Karin Holmskov Hansen, Natasha B. Leighl, Marcello Tiseo, Corey J. Langer, Myung-Ju Ahn, Dong Wan Kim, Harry J.M. Groen
Publikováno v:
Kim, D W, Tiseo, M, Ahn, M J, Reckamp, K L, Hansen, K H, Kim, S W, Huber, R M, West, H L, Groen, H J M, Hochmair, M J, Leighl, N B, Gettinger, S N, Langer, C J, Rodríguez, L G P A, Smit, E F, Kim, E S, Reichmann, W, Haluska, F G, Kerstein, D & Camidge, D R 2017, ' Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer : A randomized, multicenter phase II trial ', Journal of Clinical Oncology, vol. 35, no. 22, pp. 2490-2498 . https://doi.org/10.1200/JCO.2016.71.5904
Journal of Clinical Oncology, 35(22), 2490-2498. AMER SOC CLINICAL ONCOLOGY
Kim, D-W, Tiseo, M, Ahn, M-J, Reckamp, K L, Hansen, K H, Kim, S-W, Huber, R M, West, H L, Groen, H J M, Hochmair, M J, Leighl, N B, Gettinger, S N, Langer, C J, Paz-Ares Rodríguez, L G, Smit, E F, Kim, E S, Reichmann, W, Haluska, F G, Kerstein, D & Camidge, D R 2017, ' Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer : A Randomized, Multicenter Phase II Trial ', Journal of Clinical Oncology, vol. 35, no. 22, pp. 2490-2498 . https://doi.org/10.1200/JCO.2016.71.5904
Journal of Clinical Oncology, 35(22), 2490-2498. American Society of Clinical Oncology
Journal of Clinical Oncology, 35(22), 2490-2498. AMER SOC CLINICAL ONCOLOGY
Kim, D-W, Tiseo, M, Ahn, M-J, Reckamp, K L, Hansen, K H, Kim, S-W, Huber, R M, West, H L, Groen, H J M, Hochmair, M J, Leighl, N B, Gettinger, S N, Langer, C J, Paz-Ares Rodríguez, L G, Smit, E F, Kim, E S, Reichmann, W, Haluska, F G, Kerstein, D & Camidge, D R 2017, ' Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer : A Randomized, Multicenter Phase II Trial ', Journal of Clinical Oncology, vol. 35, no. 22, pp. 2490-2498 . https://doi.org/10.1200/JCO.2016.71.5904
Journal of Clinical Oncology, 35(22), 2490-2498. American Society of Clinical Oncology
Purpose Most crizotinib-treated patients with anaplastic lymphoma kinase gene ( ALK)–rearranged non–small-cell lung cancer (ALK-positive NSCLC) eventually experience disease progression. We evaluated two regimens of brigatinib, an investigational
Autor:
Kai Hübel, X Poire, Georg Franke, Peter Dreger, Ronald Brand, Thomas Weber, Ruzena Uddin, Stefano Guidi, Nicolaus Kröger, Theo de Witte, Giorgio Lambertenghi Deliliers, Guido Kobbe, Uwe Platzbecker, Matthias Stelljes, Liisa Volin, Christof Scheid, Simona Iacobelli, Andreas Günther, Marleen van Os, Wolfgang A. Bethge, Dominik Heim, Marie Robin, Francesco Onida, Boris V. Afanasyev, Massimo Pini
Publikováno v:
Journal of Clinical Oncology, 35(19), 2157
Journal of Clinical Oncology, 35, 19, pp. 2157-2164
Journal of Clinical Oncology, 35, 2157-2164
Journal of Clinical Oncology, 35, 19, pp. 2157-2164
Journal of Clinical Oncology, 35, 2157-2164
Purpose To compare a reduced-intensity conditioning regimen (RIC) with a myeloablative conditioning regimen (MAC) before allogeneic transplantation in patients with myelodysplastic syndrome (MDS) within a randomized trial. Patients and Methods Within
Autor:
David H. Johnson, Roy S. Herbst, Corey J. Langer, Louis Fehrenbacher, William Novotny, Eric Holmgren, Jacques Gaudreault, John Nemunaitis, David M. Jablons, Fairooz F. Kabbinavar, Russell F. DeVore, Lisa A. Damico
Publikováno v:
Journal of Clinical Oncology. 41:2305-2312
Purpose To investigate the efficacy and safety of bevacizumab plus carboplatin and paclitaxel in patients with advanced or recurrent non-small-cell lung cancer. Patients and Methods In a phase II trial, 99 patients were randomly assigned to bevacizum
Autor:
Ling Wu, Guozhi M. Gao, Jean-Jacques Body, Yasmin Rahim, Xavier Mariette, Winnie Sohn, Allan Lipton, Susie Jun, Karim Fizazi, Julie Gralow
Publikováno v:
Journal of Clinical Oncology. 27:1564-1571
Purpose Patients with bone metastases and elevated urinary N-telopeptide (uNTx), representing excessive bone resorption, are at increased risk for skeletal-related events (SREs), cancer progression, and death. Osteoclast-mediated bone resorption is r
Autor:
Melissa Wagner, Leighann Bailey, David A. Reardon, Jennifer A. Quinn, Allan H. Friedman, James J. Vredenburgh, Henry S. Friedman, James E. Herndon, Jeremy N. Rich, Annick Desjardins, Darell D. Bigner, Sith Sathornsumetee, Jennifer Marcello, John H. Sampson, Sridharan Gururangan
Publikováno v:
Journal of Clinical Oncology. 25:4722-4729
Purpose The prognosis for patients with recurrent glioblastoma multiforme is poor, with a median survival of 3 to 6 months. We performed a phase II trial of bevacizumab, a monoclonal antibody to vascular endothelial growth factor, in combination with
Publikováno v:
Journal of Clinical Oncology. 24:1454-1458
Purpose A previous report suggested the nadir serum CA-125 level within the group of patients with ovarian cancer who achieved normalization of CA-125 accurately defined the risk of relapse. Using similar CA-125 subgroups, we sought to determine if t
Autor:
Sylke Nagel, Aruna Raghavachar, Ludwig Fischer von Weikersthal, Monika Serke, Ernst-Wilhelm Schmidt, Christine Lautenschlaeger, Hans Schweisfurth, Wolfgang Schuette, Ina Dittrich, Klaus Hans, Thomas Blankenburg, Angelika Reißig
Publikováno v:
Journal of Clinical Oncology. 23:8389-8395
Purpose A phase III study to determine whether a weekly docetaxel schedule improves the therapeutic index compared with the classic 3-weekly schedule. Patients and Methods Patients with stage IIIB-IV non–small-cell lung cancer (NSCLC) were randomly
Publikováno v:
Journal of Clinical Oncology. 23:3488-3494
Purpose Irinotecan plus cisplatin (IP) chemotherapy demonstrated a promising outcome with a high complete response (CR) rate in chemotherapy-naïve patients with extensive small-cell lung cancer (SCLC). We evaluated the efficacy of induction IP chemo